Focused On-demand Library for Cytochrome c oxidase assembly protein COX15 homolog

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q7KZN9

UPID:

COX15_HUMAN

Alternative names:

Alternative UPACC:

Q7KZN9; A8K6I9; O60556; O75878; Q5TD00; Q5TD01; Q7Z3Q3; Q9NTN0

Background:

The Cytochrome c oxidase assembly protein COX15 homolog plays a crucial role in cellular energy production, specifically in the biosynthesis of heme A, an essential component of the mitochondrial respiratory chain. This protein is integral to the assembly and proper functioning of cytochrome c oxidase, the terminal enzyme complex in the mitochondrial electron transport chain.

Therapeutic significance:

Given its pivotal role in mitochondrial function, mutations in the COX15 gene leading to Mitochondrial complex IV deficiency, nuclear type 6, underscore the protein's therapeutic significance. This condition manifests with a spectrum of severe clinical features, including encephalopathy, cardiomyopathy, and persistent lactic acidosis. Targeting the COX15 protein pathway offers a promising avenue for developing treatments for mitochondrial disorders.